Need for societal-level discussion about medical cannabis, expert says

29 July 2021

New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had previously taken.

Medical Cannabis Clinics announced the data on the drug, which was legalized for medicinal use in the UK in November 2018, albeit that access is still limited.

The company, which comprises of UK-based clinics specializing in innovative cannabis-based therapies, claims that these data bolster current arguments for the drug’s potential over other existing treatment options, highlighting it as a potential solution to the opioid crisis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK